Some studies suggest that RUNX2 has the ability to transactivate its downstream target genes, such as MMP9, MMP13, VEGF, survivin, and IL-8, which are involved in tumor progression, invasion, and metastasis [31,32,33,34,35,36]. This evidence concerns the gene VEGFA and neoplasm.